Daniel Granderson[email protected]Business InsightsSaudi Arabia IVD market rose to $605M in 2022: KaloramaThe market was driven in part by COVID-19 testing, with about 44 million PCR COVID-19 tests performed through last August.June 19, 2023Business InsightsIndia IVD market sales rose to $1.4B in 2022: Kalorama InformationAccording to Kalorama's forecasts, India’s IVD market will increase at a compound annual growth rate (CAGR) of 2.4% from 2022 to 2027.April 26, 2023Business InsightsMexico IVD sales reach $794M: Kalorama InformationImmunoassays are Mexico’s leading IVD segment, followed by point-of-care and microbiology/molecular. Other POC, other molecular, and flow cytometry will be key segments to watch in coming years.April 11, 2023Business InsightsChina worth watching in $3.95B world market for molecular POC tests: Kalorama InformationCentral and provincial governments have played a significant role in the expansion of the POC testing market in China.February 22, 2023Emergency Use AuthorizationCOVID-19 tests attempt to prove at-home testing concept can workThese COVID-19 tests were granted separate emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) earlier in 2021 and all require nasal swab specimens from patients.August 22, 2021Page 1 of 1Top StoriesFDA ClearanceAmgen gets FDA approval for small cell lung cancer therapyAmgen announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved its therapy tarlatamab, to be marketed under the name Imdelltra, for the treatment of extensive-stage small cell lung cancer (ES-SCLC).Artificial IntelligenceBacklog of unresolved medical diagnoses leads to new method for clinical exome reanalysisStockT2 Biosystems to sell $8M in stock in private placementFDA Warning LetterFDA issues warning for Cue Health COVID-19 testsSponsor ContentVisit our Molecular Diagnostics Community